MOTS-C and Insulin Resistance Research: Mitochondrial Peptide, Glucose Metabolism and Type 2 Diabetes Biology

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial genome — a discovery that challenged the long-held assumption that mitochondrial DNA (mtDNA) encodes only structural components of the respiratory chain. As a mitochondria-derived peptide (MDP), MOTS-C has emerged as a key inter-organelle and systemic hormone, regulating glucose metabolism, insulin sensitivity, and cellular stress responses. Its biology sits at the intersection of mitochondrial function, metabolic homeostasis, and ageing — making it an important research tool for investigators studying type 2 diabetes, obesity, and metabolic syndrome. All research discussed is Research Use Only (RUO).

---

Why Mitochondria Signal to the Nucleus and Circulation

For decades, mitochondria were understood as passive organelles responding to cellular energetic demands through retrograde signalling (stress signals from mitochondria to the nucleus). The discovery of mitochondria-derived peptides — short open reading frames within mtDNA that encode bioactive peptides — has revealed that mitochondria are also active signalling entities that communicate metabolic status to the rest of the cell, to adjacent cells, and to distant tissues through circulating MDPs.

MOTS-C was identified by Chang et al. in 2015 within the 12S rRNA region of human mtDNA — an area not previously known to encode proteins. The peptide sequence is highly conserved across primate species and partially conserved in mammals, suggesting functional importance maintained by evolutionary selection pressure. This conservation is remarkable given that mitochondrial DNA generally evolves faster than nuclear DNA.

---

MOTS-C and Insulin Sensitivity: Core Mechanisms

AMPK Activation

AMP-activated protein kinase (AMPK) is the cell’s master energy sensor — activated when AMP:ATP ratio rises (indicating energy deficit) and promoting catabolic pathways (fatty acid oxidation, glucose uptake) while inhibiting anabolic pathways (lipid synthesis, protein synthesis). MOTS-C activates AMPK through a mechanism that is independent of the canonical AMP-mediated allosteric pathway:

• MOTS-C enters cells (including skeletal muscle cells) and translocates to the nucleus under metabolic stress
• In the nucleus, MOTS-C acts as a transcription regulator — binding to AMPK-related transcriptional elements and driving expression of genes involved in glucose uptake and fatty acid oxidation
• MOTS-C additionally stimulates direct AMPK phosphorylation (Thr172) through upstream kinase activation — including LKB1 and CaMKKβ pathway activation

AMPK activation downstream of MOTS-C drives skeletal muscle glucose transporter 4 (GLUT4) translocation to the plasma membrane — a key mechanism for insulin-independent glucose uptake. This is particularly important in the context of insulin resistance, where GLUT4 translocation is impaired due to defective insulin signalling through IRS-1/PI3K/Akt.

Folate Cycle and Methionine Metabolism

An unexpected finding in the original MOTS-C characterisation was its interaction with the folate cycle. MOTS-C inhibits the folate cycle enzyme AICAR transformylase (ATIC), leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — which is itself a well-characterised AMPK activator (the mechanism of metformin’s action, and the basis for the AICAR research compound used in exercise biology studies). This AICAR-mediated AMPK activation represents a novel indirect mechanism through which MOTS-C enhances cellular metabolic flexibility and insulin sensitivity.

Fatty Acid Oxidation Upregulation

Beyond glucose metabolism, MOTS-C upregulates mitochondrial fatty acid oxidation (FAO) through AMPK-PGC-1α pathway activation. PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis and oxidative metabolism. MOTS-C-driven PGC-1α activity increases mitochondrial copy number, enhances the capacity of skeletal muscle to oxidise fatty acids, and reduces intramyocellular lipid accumulation — a critical contributor to skeletal muscle insulin resistance (lipotoxicity).

---

MOTS-C in Preclinical Insulin Resistance and Diabetes Models

High-Fat Diet Mouse Models

The most extensively used MOTS-C animal model is the high-fat diet (HFD) mouse — which develops obesity, systemic insulin resistance, hyperglycaemia, and dyslipidaemia within 8–12 weeks. MOTS-C injection (5–15 mg/kg SC or IP) in HFD mice produces:

• Significant reduction in fasting blood glucose (20–40% reduction in some studies) within 2 weeks
• Improved insulin tolerance test (ITT) responses — faster blood glucose clearance following insulin challenge, indicating improved peripheral insulin sensitivity
• Improved glucose tolerance test (GTT) results — better handling of exogenous glucose load
• Reduced hepatic glucose output — MOTS-C reduces gluconeogenesis in the liver through AMPK-mediated inhibition of PEPCK and G6Pase expression
• Body weight reduction in some but not all studies — partly attributable to increased energy expenditure through enhanced FAO

Genetically Obese Models (db/db, ob/ob)

In leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice — which develop severe obesity and type 2 diabetes — MOTS-C administration similarly improves metabolic parameters. Importantly, the effect is maintained even in the absence of normal leptin signalling, indicating MOTS-C acts through leptin-independent pathways (AMPK, not the leptin-AMPK axis).

Skeletal Muscle-Specific Mechanisms

Skeletal muscle accounts for approximately 80% of insulin-stimulated glucose uptake in the postprandial state and is the primary site of peripheral insulin resistance in T2DM. Isotopically labelled glucose uptake studies in MOTS-C-treated rodents confirm that the primary site of MOTS-C’s insulin-sensitising effect is skeletal muscle — with lesser contributions from adipose tissue and liver. This muscle-centric mechanism aligns with MOTS-C’s origin as a mitochondria-derived peptide, given that skeletal muscle is the highest mitochondrial density tissue in the body.

---

Circulating MOTS-C as a Biomarker

MOTS-C is detectable in human plasma, and several clinical studies have measured circulating MOTS-C across metabolic disease states:

• T2DM: Circulating MOTS-C is significantly lower in T2DM patients compared to age-matched controls — suggesting that declining mitochondrial MOTS-C secretion may contribute to metabolic deterioration in diabetes
• Obesity: MOTS-C levels are inversely correlated with BMI and visceral fat mass in cross-sectional studies
• Insulin resistance (non-diabetic): HOMA-IR (homeostatic model assessment of insulin resistance) negatively correlates with plasma MOTS-C — even in the absence of frank diabetes
• Exercise: Acute exercise increases plasma MOTS-C — consistent with MOTS-C’s role as a metabolic adaptation signal during energy demand. Chronic exercise training is associated with higher resting MOTS-C, potentially contributing to the metabolic benefits of regular physical activity

The inverse relationship between MOTS-C levels and metabolic disease severity has generated interest in MOTS-C as a biomarker for mitochondrial health and metabolic reserve — though standardisation of plasma assays and determination of reference ranges across ages and populations remain active research areas.

---

MOTS-C and Ageing: The Mitochondrial Decline Hypothesis

Mitochondrial function declines progressively with age — reduced mtDNA copy number, increased mtDNA mutations, impaired electron transport chain activity, and reduced mitochondrial biogenesis all characterise the aged mitochondrial phenotype. As a mitochondria-derived peptide, MOTS-C production declines with mitochondrial ageing:

• Plasma MOTS-C levels decline significantly with age in multiple human cohorts
• The age-related decline in MOTS-C mirrors the decline in skeletal muscle mitochondrial respiratory capacity
• In aged mice, MOTS-C supplementation partially restores skeletal muscle metabolic flexibility — improving glucose uptake and exercise performance toward levels seen in younger animals

This positions MOTS-C within the broader mitohormesis framework: the hypothesis that mitochondria function as stress sensors that, when properly signalling, promote systemic adaptive resilience — and that age-related failure of mitochondrial signalling contributes to metabolic and physical decline. MOTS-C may represent one of the key molecular signals through which mitochondrial function communicates metabolic health to peripheral tissues.

---

MOTS-C Variants and mtDNA Polymorphisms

A research discovery with significant translational implications: the MOTS-C peptide sequence varies between individuals based on mitochondrial haplogroup — the inherited mtDNA variants that differ across human populations and have been associated with varying longevity and metabolic disease risk in epidemiological studies. Specific MOTS-C variants (particularly the K14Q polymorphism in haplogroup D) show altered signalling properties — with some variants showing greater AMPK activation potency and others reduced activity.

This polymorphic biology raises the possibility that population-level differences in MOTS-C variant activity contribute to the well-documented differences in T2DM and metabolic syndrome prevalence across mtDNA haplogroup populations — an intersection of mitochondrial genetics, population biology, and metabolic disease research that remains largely unexplored.

---

Research Applications for UK Metabolic Disease Investigators

For researchers studying insulin resistance, type 2 diabetes, and mitochondrial biology, MOTS-C provides a tool for:

• Dissecting AMPK-independent versus AMPK-dependent mechanisms of insulin sensitisation in muscle cell lines and primary myotubes
• Investigating AICAR-AMPK axis activation as a metabolic signalling pathway
• Characterising MOTS-C plasma levels as a biomarker in human metabolic disease cohort studies
• Testing exercise-mimetic effects of MOTS-C in sedentary mouse models (MOTS-C has been described as recapitulating some molecular effects of exercise training)
• Studying mitochondrial-nuclear communication in the context of metabolic stress